Julius Knowles Ph.D Overview
- Firm
- Mass General Bri...
- Primary Position
-
Partner
- Primary Industry
-
Healthcare
- Active Board Seats
-
5
- Med. Deal Size
-
- Med. Valuation
-
Julius Knowles Ph.D General Information
Biography
Dr. Julius Knowles serves as a Partner at Mass General Brigham. He serves as an Investment Committee Member at Myeloma Investment Fund. He was Vice President, Business Development, at Novacea and Structural Genomix, and Research and Development Planning Director at Vertex Pharmaceuticals. He has an MBA in Finance from Wharton Business School, an M.Sc. in Chemistry from UC Berkeley, and a BA with Distinction in Chemistry from Carleton College. He represents Mass General Brigham Ventures on the board of Abcuro, Keros, Paros, Proximity, and SwanBio, and as a board observer at ROME, QurAlis, and Triplet Therapeutics. He also holds a Ph.D degree.
Contact Information
Address
- 399 Revolution Drive
- Suite 999
- Somerville, MA 02145
- United States
Julius Knowles Ph.D Positions (3)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
Mass General Brigham | Company | Partner | Somerville, MA | Hospitals/Inpatient Services | |
Mass General Brigham Innovation | Investor | Partner | Cambridge, MA | Corporate Venture Capital | |
Mass General Brigham Ventures | Investor | Partner | Somerville, MA | Venture Capital |
Julius Knowles Ph.D Board Seats (5)
Company | Industry | Ownership Status | Financing Status | Location | Since |
---|---|---|---|---|---|
Abcuro | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Newton, MA | |
Keros Therapeutics | Biotechnology | Publicly Held | Formerly VC-backed | Lexington, MA | |
Myeloma Investment Fund | Norwalk, CT | ||||
Proximity Therapeutics | Biotechnology | Privately Held (backing) | Venture Capital-Backed | Cambridge, MA | |
SwanBio Therapeutics | Drug Discovery | Acquired/Merged (Operating Subsidiary) | Formerly VC-backed | Bala Cynwyd, PA |
Julius Knowles Ph.D Lead Partner on Deals (12)
Julius Knowles Ph.D has been the lead partner on 12 deals. Their latest deal was with ROME Therapeutics, a drug discovery company. The deal was made for on 14-Aug-2023.
Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
---|---|---|---|---|---|---|
ROME Therapeutics | 14-Aug-2023 | Early Stage VC (Series B) | Completed | Drug Discovery | Boston, MA | |
Abcuro | 11-Aug-2023 | Completed | Drug Discovery | Newton, MA | ||
SwanBio Therapeutics | 08-May-2022 | Completed | Drug Discovery | Bala Cynwyd, PA | ||
Paros Bio | 01-Aug-2021 | Completed | Biotechnology | Boston, MA | ||
Abcuro | 07-Jan-2021 | Completed | Drug Discovery | Newton, MA | ||
Abcuro | 07-Jan-2021 | Completed | Drug Discovery | Newton, MA | ||
ROME Therapeutics | 27-Apr-2020 | Completed | Drug Discovery | Boston, MA | ||
SwanBio Therapeutics | 23-Apr-2020 | Completed | Drug Discovery | Bala Cynwyd, PA | ||
Keros Therapeutics | 04-Mar-2020 | Later Stage VC (Series C) | Completed | Biotechnology | Lexington, MA | |
Keros Therapeutics | 07-Jan-2019 | Early Stage VC (Series B) | Completed | Biotechnology | Lexington, MA |
Julius Knowles Ph.D Network (138)
Board Members (84)
Name | Company | Representing | Location | From |
---|---|---|---|---|
Ohad Hammer | Keros Therapeutics | Pontifax Venture Capital | Lexington, MA | |
Alex Martin | Abcuro | Self | Newton, MA | |
Abcuro | Self | Newton, MA | ||
Tilos Therapeutics | Self | Lexington, MA | ||
ROME Therapeutics | Self | Boston, MA |
Portfolio Executives (51)
Name | Company | Role | Deal date | Location |
---|---|---|---|---|
Wenyan Miao Ph.D | ROME Therapeutics | Vice President, Immunology | 14-Aug-2023 | Boston, MA |
Heike Keilhack Ph.D | ROME Therapeutics | Chief Scientific Officer | 14-Aug-2023 | Boston, MA |
ROME Therapeutics | Co-Founder & Board Member | 14-Aug-2023 | Boston, MA | |
ROME Therapeutics | Chief Financial Officer & Chief Business Officer | 14-Aug-2023 | Boston, MA | |
ROME Therapeutics | Scientific Co-Founder | 14-Aug-2023 | Boston, MA |
Fund Team Members (3)
Name | Investor | Fund | Fund Location |
---|---|---|---|
Meredith Fisher Ph.D | Mass General Brigham Ventures | Mass General Brigham Fund III | Somerville, MA |
Roger Kitterman | Mass General Brigham Ventures | Mass General Brigham Fund III | Somerville, MA |
Mass General Brigham Ventures | Somerville, MA |
Julius Knowles Ph.D Affiliated Funds (2)
Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
---|---|---|---|---|---|---|---|---|
Partners Innovation Fund II | Mass General Brigham Innovation | Venture Capital - Early Stage | Closed | 2016 | ||||
Mass General Brigham Fund III | Mass General Brigham Ventures | Venture - General | Closed | 2021 |
Julius Knowles Ph.D FAQs
-
Who is Julius Knowles Ph.D?
Dr. Julius Knowles serves as a Partner at Mass General Brigham.
-
How much does Julius Knowles Ph.D typically invest?
Julius Knowles Ph.D's median deal size is
. -
What is Julius Knowles Ph.D’s main position?
Julius Knowles Ph.D’s primary position is Partner.
-
What are the contact details for Julius Knowles Ph.D?
Julius Knowles Ph.D’s email address is jj
and his phone number is +1 (617) . -
How many active board seats does Julius Knowles Ph.D hold?
Julius Knowles Ph.D holds 5 board seats including Abcuro, Keros Therapeutics, Myeloma Investment Fund, Proximity Therapeutics, and SwanBio Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »